Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term AMG 827 extension study in Crohn's disease
NL-OMON36733Phase 2Active, not recruiting
- Sponsor
- Amgen
- Start
- May 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of brodalumab in Crohn's disease, sponsored by Amgen. Started May 2011; status: active, not recruiting.
02
Drugs
brodalumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NL-OMON36733.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36733.